Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | WNT3 | P56703 | 1/20 | 0.33 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910391 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6HSD17B10LMNACYP2C19 | |
| SCHEMBL1697363 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6HSD17B10LMNACYP2C19 | |
| SCHEMBL22570260 | 0.94 | ALDH1A1 (0.39) | CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL16979500 | 0.94 | ALDH1A1 (0.39) | CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL21341484 | 0.87 | ALDH1A1 (0.34) | CYP3A4CYP2D6LMNAALDH1A1RIPK1 | |
| SCHEMBL10120394 | 0.87 | ALDH1A1 (0.34) | CYP3A4CYP2D6LMNAALDH1A1RIPK1 | |
| Pivalate SCHEMBL29159394 | 0.80 | LMNA (0.46) | CYP3A4CYP2D6HSD17B10LMNACYP2C19 | |
| SCHEMBL27363236 | 0.78 | CYP3A4 (0.46) | CYP3A4CYP2D6HSD17B10LMNACYP2C19 | |
| SCHEMBL15119983 | 0.78 | HSD17B10 (0.37) | HSD17B10LMNACYP2C19ALDH1A1CA12 | |
| SCHEMBL10052110 | 0.78 | HSD17B10 (0.37) | HSD17B10LMNACYP2C19ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CYP3A4 3475/4885CYP2D6 3871/4885HSD17B10 2976/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | CYP3A4 4485/4885CYP2D6 4327/4885HSD17B10 2384/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | CYP3A4 787/4885CYP2D6 1111/4885HSD17B10 2891/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CYP3A4 3475/4885CYP2D6 3871/4885HSD17B10 2976/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | CYP3A4 120/4885CYP2D6 138/4885HSD17B10 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.